Eye Point Pharmaceuticals, Inc. EYPT
We take great care to ensure that the data presented and summarized in this overview for EyePoint Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EYPT
View all-
Cormorant Asset Management, LP Boston, MA6.89MShares$64.7 Million8.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.76MShares$44.6 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.76MShares$35.3 Million3.33% of portfolio
-
Franklin Resources Inc San Mateo, CA3.39MShares$31.8 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$26.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.47MShares$23.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.4MShares$22.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.05MShares$19.2 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.6MShares$15.1 Million0.02% of portfolio
-
Essex Woodlands Management, Inc. The Woodlands, TX1.55MShares$14.6 Million9.32% of portfolio
Latest Institutional Activity in EYPT
Top Purchases
Top Sells
About EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Insider Transactions at EYPT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 03
2024
|
David R Guyer |
SELL
Open market or private sale
|
Direct |
11,625
-75.86%
|
$116,250
$10.3 P/Share
|
Jun 03
2024
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,775
+26.29%
|
$29,325
$3.38 P/Share
|
May 25
2024
|
George Elston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,627
-7.1%
|
$39,897
$11.16 P/Share
|
May 25
2024
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+12.8%
|
-
|
May 14
2024
|
David R Guyer |
SELL
Open market or private sale
|
Direct |
11,625
-67.69%
|
$139,500
$12.65 P/Share
|
May 14
2024
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,775
+23.91%
|
$29,325
$3.38 P/Share
|
May 06
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
850,000
+4.88%
|
$10,200,000
$12.03 P/Share
|
Apr 18
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
581,765
+3.79%
|
$10,471,770
$18.26 P/Share
|
Mar 30
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,546
-10.04%
|
$510,920
$20.67 P/Share
|
Mar 30
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,404
+17.32%
|
-
|
Feb 27
2024
|
Jay S. Duker President and CEO |
BUY
Bona fide gift
|
Indirect |
2,500
+10.0%
|
-
|
Feb 27
2024
|
Jay S. Duker President and CEO |
SELL
Bona fide gift
|
Direct |
2,500
-7.83%
|
-
|
Feb 20
2024
|
Jay S. Duker President and CEO |
BUY
Bona fide gift
|
Indirect |
20,000
+50.0%
|
-
|
Feb 20
2024
|
Jay S. Duker President and CEO |
SELL
Bona fide gift
|
Direct |
20,000
-38.52%
|
-
|
Feb 13
2024
|
Nancy Lurker Executive Vice Chair |
BUY
Bona fide gift
|
Indirect |
74,681
+37.05%
|
-
|
Feb 13
2024
|
Nancy Lurker Executive Vice Chair |
SELL
Bona fide gift
|
Direct |
74,681
-47.26%
|
-
|
Feb 09
2024
|
Nancy Lurker Executive Vice Chair |
SELL
Payment of exercise price or tax liability
|
Direct |
14,943
-4.42%
|
$418,404
$28.8 P/Share
|
Feb 09
2024
|
Nancy Lurker Executive Vice Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
37,534
+10.3%
|
-
|
Feb 09
2024
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,533
-3.24%
|
$98,924
$28.8 P/Share
|
Feb 09
2024
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,967
+10.2%
|
-
|
Last 12 Months Summary
Open market or private purchase | 4.79M shares |
---|---|
Exercise of conversion of derivative security | 559K shares |
Bona fide gift | 97.2K shares |
Payment of exercise price or tax liability | 109K shares |
---|---|
Bona fide gift | 97.2K shares |
Open market or private sale | 6.84M shares |